Tags

Type your tag names separated by a space and hit enter

PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization.
J Bone Miner Res. 2016 Jan; 31(1):180-9.JB

Abstract

Patients with hypoparathyroidism have low circulating parathyroid (PTH) levels and higher cancellous bone volume and trabecular thickness. Treatment with PTH(1-84) was shown to increase abnormally low bone remodeling dynamics. In this work, we studied the effect of 1-year or 2-year PTH(1-84) treatment on cancellous and cortical bone mineralization density distribution (Cn.BMDD and Ct.BMDD) based on quantitative backscattered electron imaging (qBEI) in paired transiliac bone biopsy samples. The study cohort comprised 30 adult hypoparathyroid patients (14 treated for 1 year; 16 treated for 2 years). At baseline, Cn.BMDD was shifted to higher mineralization densities in both treatment groups (average degree of mineralization Cn.CaMean +3.9% and +2.7%, p < 0.001) compared to reference BMDD. After 1-year PTH(1-84), Cn.CaMean was significantly lower than that at baseline (-6.3%, p < 0.001), whereas in the 2-year PTH(1-84) group Cn.CaMean did not differ from baseline. Significant changes of Ct.BMDD were observed in the 1-year treatment group only. The change in histomorphometric bone formation (mineralizing surface) was predictive for Cn.BMDD outcomes in the 1-year PTH(1-84) group, but not in the 2-year PTH(1-84) group. Our findings suggest higher baseline bone matrix mineralization consistent with the decreased bone turnover in hypoparathyroidism. PTH(1-84) treatment caused differential effects dependent on treatment duration that were consistent with the histomorphometric bone formation outcomes. The greater increase in bone formation during the first year of treatment was associated with a decrease in bone matrix mineralization, suggesting that PTH(1-84) exposure to the hypoparathyroid skeleton has the greatest effects on BMDD early in treatment.

Authors+Show Affiliations

Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of Social Health Insurance Vienna (WGKK) and Austrian Social Insurance for Occupational Risk (AUVA) Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria.Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of Social Health Insurance Vienna (WGKK) and Austrian Social Insurance for Occupational Risk (AUVA) Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria.Regional Bone Center Helen Hayes Hospital, West Haverstraw, New York, NY, USA. Metabolic Bone Diseases Unit, College of Physicians and Surgeons, Columbia University New York, NY, USA.Regional Bone Center Helen Hayes Hospital, West Haverstraw, New York, NY, USA.Metabolic Bone Diseases Unit, College of Physicians and Surgeons, Columbia University New York, NY, USA.Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of Social Health Insurance Vienna (WGKK) and Austrian Social Insurance for Occupational Risk (AUVA) Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria.Metabolic Bone Diseases Unit, College of Physicians and Surgeons, Columbia University New York, NY, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

26111772

Citation

Misof, Barbara M., et al. "PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization." Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, vol. 31, no. 1, 2016, pp. 180-9.
Misof BM, Roschger P, Dempster DW, et al. PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization. J Bone Miner Res. 2016;31(1):180-9.
Misof, B. M., Roschger, P., Dempster, D. W., Zhou, H., Bilezikian, J. P., Klaushofer, K., & Rubin, M. R. (2016). PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization. Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, 31(1), 180-9. https://doi.org/10.1002/jbmr.2588
Misof BM, et al. PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization. J Bone Miner Res. 2016;31(1):180-9. PubMed PMID: 26111772.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization. AU - Misof,Barbara M, AU - Roschger,Paul, AU - Dempster,David W, AU - Zhou,Hua, AU - Bilezikian,John P, AU - Klaushofer,Klaus, AU - Rubin,Mishaela R, Y1 - 2015/07/28/ PY - 2015/01/27/received PY - 2015/06/20/revised PY - 2015/06/23/accepted PY - 2015/6/27/entrez PY - 2015/6/27/pubmed PY - 2016/11/1/medline KW - BMDD KW - BONE MINERALIZATION DENSITY DISTRIBUTION KW - HYPOPARATHYROIDISM KW - QBEI KW - QUANTITATIVE BACKSCATTERED ELECTRON IMAGING KW - TRANSILIAC BONE BIOPSY SP - 180 EP - 9 JF - Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research JO - J Bone Miner Res VL - 31 IS - 1 N2 - Patients with hypoparathyroidism have low circulating parathyroid (PTH) levels and higher cancellous bone volume and trabecular thickness. Treatment with PTH(1-84) was shown to increase abnormally low bone remodeling dynamics. In this work, we studied the effect of 1-year or 2-year PTH(1-84) treatment on cancellous and cortical bone mineralization density distribution (Cn.BMDD and Ct.BMDD) based on quantitative backscattered electron imaging (qBEI) in paired transiliac bone biopsy samples. The study cohort comprised 30 adult hypoparathyroid patients (14 treated for 1 year; 16 treated for 2 years). At baseline, Cn.BMDD was shifted to higher mineralization densities in both treatment groups (average degree of mineralization Cn.CaMean +3.9% and +2.7%, p < 0.001) compared to reference BMDD. After 1-year PTH(1-84), Cn.CaMean was significantly lower than that at baseline (-6.3%, p < 0.001), whereas in the 2-year PTH(1-84) group Cn.CaMean did not differ from baseline. Significant changes of Ct.BMDD were observed in the 1-year treatment group only. The change in histomorphometric bone formation (mineralizing surface) was predictive for Cn.BMDD outcomes in the 1-year PTH(1-84) group, but not in the 2-year PTH(1-84) group. Our findings suggest higher baseline bone matrix mineralization consistent with the decreased bone turnover in hypoparathyroidism. PTH(1-84) treatment caused differential effects dependent on treatment duration that were consistent with the histomorphometric bone formation outcomes. The greater increase in bone formation during the first year of treatment was associated with a decrease in bone matrix mineralization, suggesting that PTH(1-84) exposure to the hypoparathyroid skeleton has the greatest effects on BMDD early in treatment. SN - 1523-4681 UR - https://www.unboundmedicine.com/medline/citation/26111772/PTH_1_84__Administration_in_Hypoparathyroidism_Transiently_Reduces_Bone_Matrix_Mineralization_ L2 - https://doi.org/10.1002/jbmr.2588 DB - PRIME DP - Unbound Medicine ER -